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Glucose is an important inducer of insulin secretion,
but it also stimulates long-term adaptive changes in
gene expression that can either promote or antago-
nize the proliferative potential and function of b cells.
Here, we have generated time-resolved profiles of
enhancer and transcriptional activity in response to
glucose in the INS-1E pancreatic b cell line. Our
data outline a biphasic response with a first tran-
scriptional wave during which metabolic genes are
activated, and a secondwavewhere cell-cycle genes
are activated and b cell identity genes are repressed.
The glucose-sensing transcription factor ChREBP
directly activates first wave enhancers, whereas
repression and activation of second wave enhancers
are indirect. By integrating motif enrichment within
late-regulated enhancers with expression profiles
of the associated transcription factors, we have iden-
tified multiple putative regulators of the second
wave. These include RORg, the activity of which is
important for glucose-induced proliferation of both
INS-1E and primary rat b cells.
INTRODUCTION
Pancreatic b cells play a key role in the regulation of glucose up-
take and metabolism. They respond to a rise in blood glucose by
increasing the secretion of insulin, which in turn increases the
storage and utilization of glucose in peripheral tissues. Type 2
diabetes (T2D) is caused by an inability of the b cells to secreteCell Re
This is an open access article under the CC BY-Nsufficient amounts of insulin to meet the demands for nutrient
use and storage. Insulin resistance in liver and peripheral tissues
contributes significantly to this imbalance, but whether insulin
resistant subjects develop hyperglycemia appears to depend
on their ability to expand the b cell mass or capacity in response
to the increased metabolic load. Conversely, b cells of type 2
diabetics respond poorly to a glucose challenge; however, the
etiology of b cell dysfunction in T2D remains controversial. Tradi-
tionally, the deficit in b cell capacity has been ascribed to
increased apoptosis, but recent studies suggest that b cell dedif-
ferentiation plays a dominant role in b cell failure in T2D (Talchai
et al., 2012). Interestingly, during the progression to insulin resis-
tance and T2D, it appears that glucose itself acts both to pro-
mote expansion of b cell mass to meet higher demands of insulin
(Levitt et al., 2011; Lingohr et al., 2002) and as a stressor that can
lead to dysfunction, so-called glucotoxicity (Brun et al., 2015;
Prentki and Nolan, 2006). However, so far the changes in b cell
gene expression underlying these adaptive and pathogenic ef-
fects are far from understood, and genome-wide insight into
transcriptional reprogramming of the b cell genome by glucose
is missing.
Several recent studies have implicated the transcription factor
carbohydrate response element binding protein (ChREBP) in
glucose-induced regulation of b cell gene expression and func-
tion (Boergesen et al., 2011; da Silva Xavier et al., 2006; Metukuri
et al., 2012; Poungvarin et al., 2012). ChREBP is a basic helix-
loop-helix leucine zipper (bHLH-LZ) transcription factor that
exerts its actions by binding to DNA on carbohydrate response
elements (ChoREs) together with another bHLH-LZ protein
called Max-like protein X (Mlx) (Ma et al., 2005). ChREBP senses
glucose by multiple different mechanisms, which vary between
cell types, but most signaling converge onto a glucose sensing
module in the N terminus, the deletion of which renders ChREBPports 16, 2359–2372, August 30, 2016 ª 2016 The Author(s). 2359
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
constitutively active (Boergesen et al., 2011; Li et al., 2006).
ChREBP has been shown to promote both glucose-induced b
cell proliferation (Metukuri et al., 2012) and dysfunction (Poung-
varin et al., 2012), thereby reflecting the dual effects of glucose
on b cell function. However, while a role for ChREBP at these
and additional functional levels has been demonstrated, only a
few ChREBP target genes are known in b cells, and the mecha-
nistic understanding of these pleiotropic effects of ChREBP is
incomplete.
Here, we have generated time-resolved profiles of the tran-
scriptional response to glucose in INS-1E pancreatic b cells
and used gain- and loss-of-function studies and chromatin
immunoprecipitation sequencing (ChIP-seq) to dissect the role
of ChREBP herein. Our data outline aChREBP-initiated, biphasic
response with acute (1–2 hr) induction of genes involved in
glucose and lipid metabolism and delayed (4–12 hr) induction
of cell-cycle genes along with repression of b cell identity genes.
By integrative bioinformatics analyses, we have identified multi-
ple drivers of the cell-cycle gene program, including RAR-related
orphan receptor (ROR) g, which we demonstrate is a direct
ChREBP target gene important for induction of b cell proliferation
by glucose.
RESULTS
Transcriptional Reprogramming of INS-1E b Cells
following High Glucose Exposure
To map the transcriptional response to high glucose in b cells,
we preincubated INS-1E cells at 5 mM glucose for 24 hr and
performed total RNA-seq following 0, 1, 2, 4, and 12 hr exposure
to 25 mM glucose. Exposure to high glucose for 12 hr led to a
pronounced reprogramming of the INS-1E cell transcriptome
with 2,042 and 1,700 genes significantly induced and repressed,
respectively (FDR % 0.05) (Figure 1A). The INS-1E transcrip-
tome is similar to that of rat pancreatic islets (Figures S1A–
S1C) (Bensellam et al., 2009) compared to other tissues in the
rat body map (Yu et al., 2014) and the glucose-induced changes
in gene expression are comparable between INS-1E cells and
rat pancreatic islets (Figures S1D–S1F) (Bensellam et al.,
2009). Interestingly, genes induced by glucose in INS-1E cells
are also enriched among genes that are expressed to higher
levels in islets from type 2 diabetics compared with islets from
non-diabetic controls, whereas genes repressed by glucose
are enriched among genes that are expressed to lower levels
in diabetic compared with non-diabetic islets (Figures S1G
and S1H).
Pathway analysis revealed that genes induced by glucose
in INS-1E cells are enriched in glucose metabolism and cell-
cycle pathways, whereas genes repressed by glucose among
others are associated with insulin secretion and maturity-onset
diabetes of the young (MODY) (Figure 1B). To investigate
the changes in transcriptional activity underlying the glucose-
induced reprogramming of the b cell transcriptome, we used
our recently developed computational method, iRNA-seq (Mad-
sen et al., 2015). iRNA-seq identifies reads that map uniquely to
introns of each gene and estimates changes in transcription
levels between conditions based on this information. These
changes correlate well with those determined by other methods2360 Cell Reports 16, 2359–2372, August 30, 2016for assessment of transcriptional activity (Madsen et al., 2015;
Schmidt et al., 2015). In line with these recent studies, analysis
of intron reads allowed for much better detection of acute
gene regulation by glucose compared with exon reads (Figures
S1I–S1K). We identified in total 5,302 genes that were signifi-
cantly regulated at the primary or mature transcript levels be-
tween 0 hr and one or more of the other time points; and using
fuzzy cluster analysis, these genes were grouped into four clus-
ters based on temporal changes in primary transcript (Figure 1C).
The four clusters display enrichment of distinct metabolic path-
ways with genes acutely induced by high glucose (cluster 1)
being enriched in glucose and steroid metabolism pathways,
whereas cell-cycle genes are enriched in the late-induced clus-
ter (cluster 2), and genes involved in insulin secretion and
MODY are enriched in the late-repressed cluster (cluster 4) (Fig-
ure 1C; Table S1). Consistently, gene cluster 4 displays a higher
overlap with genes expressed specifically in pancreatic islets
(Table S2) (http://www.betacell.org/) compared with constitutive
genes and the three other gene clusters (Figure 1D). Interest-
ingly, acutely induced genes are more likely to also be induced
by glucose in hepatocytes (Ma et al., 2006) than the late-induced
genes that appear to be induced by glucose in a b cell specific
manner (Figure 1E). Collectively, our temporal genome-wide
analysis of the transcriptional response to glucose in pancreatic
b cells reveals a biphasic transcriptional response leading to
acute induction of genes involved in glucose and lipid meta-
bolism, delayed activation of proliferative genes, and delayed
repression of genes involved in b cell function.
ChREBP Is a Central Mediator of Glucose-Induced
Transcriptional Reprogramming in b Cells
To investigate the role of ChREBP in the global transcriptional re-
programming of b cells by glucose, we transduced INS-1E cells
with an adenovirus expressing an N-terminally truncated consti-
tutive active ChREBP (Ad-CA-ChREBP) (Boergesen et al., 2011)
or GFP (Ad-GFP) as a control. Notably, analysis of total RNA-seq
data from Ad-CA-ChREBP and Ad-GFP transduced INS-1E re-
vealed that CA-ChREBP is capable of regulating the majority of
the glucose-regulated genes in b cells (Figures 2A and 2B)
including genes involved in cell proliferation and MODY/insulin
secretion (Figures 2C and 2D). Next, we transfected INS-1E cells
with small interfering (si)RNA targeting ChREBP (siChREBP) or a
negative control (siControl), resulting in robust knock down
of ChREBP, and decreased glucose-induction of well-known
ChREBP target genes such as Pklr and Gpd1 (Figures S2A and
S2B). mRNA-seq profiling of the response to 12 hr of high
glucose in siChREBP- and siControl-cells revealed that ChREBP
depletion efficiently blunts the regulation of gene programs by
glucose (Figures 2E, 2F, and S2C). Collectively, these data place
ChREBP as a key regulator of glucose-induced transcriptional
reprogramming of b cells.
Glucose Induces Reprogramming of Enhancer Activity
and Architecture
To investigate the transcriptional mechanisms underlying re-
programming of the b cell transcriptome by glucose, we first
determined the effects of 2 and 12 hr glucose exposure on
enhancer activity in INS-1E cells. Using mediator complex
Figure 1. High Glucose Induces Biphasic Transcriptional Changes in INS-1E b Cells
Following 24 hr preincubation in 5mMglucosemedium, INS-1E cells were switched to fresh 5mMmedium, and 25mMglucose was added for 1, 2, 4, and 12 hr in
a reverse time course before simultaneous harvest of all samples for total RNA-seq. Changes in mRNA expression and transcriptional activity were determined
using the iRNA-seq pipeline.
(A) MA-plot plot showing mean expression level versus log2 fold change (induced by 12 hr high glucose exposure) in tag count within exons of Ensembl gene
bodies. The green and red dots represent genes that were determined to be induced and repressed, respectively (FDR% 0.05).
(B) Heatmap representing -log10(p value) for the top enriched pathways for genes induced and repressed by high glucose (12 hr versus 0 hr).
(C) Fuzzy cluster analysis of the temporal changes in transcriptional activity (intron reads) of all genes with dynamic expression pattern (i.e., with difference
[FDR% 0.05] between 0 hr and any time point at either nascent or mature transcript level). The top three enriched pathways and gene examples are listed for each
cluster.
(D and E) Bar diagrams illustrating the significance in a one-tailed chi-square test of the overlap between the four gene clusters defined in (C) and lists of islet-
specific genes (D) and a list of genes induced by glucose in primary hepatocytes (E) compared with the overlap between the different lists and constitutive genes.
(E: cluster 1 versus cluster 2: p = 0.003).subunit 1 (MED1) ChIP-seq as a surrogate for enhancer activity
(Heintzman et al., 2009), we identified in total 20,632 putative en-
hancers with a significant change in activity between the 0 hr and
the 2 and/or 12 hr time points (Figures S3A and S3B). Using fuzzy
cluster analysis, we grouped these regions into six clusters with
distinct glucose-induced temporal changes in enhancer activity
(Figure 3A). For all enhancer clusters, we found that glucose-
induced changes inMED1 occupancy are associated with corre-
sponding changes in enhancer RNA (eRNA) transcription (Kim
et al., 2010) and in chromatin accessibility, as assessed by
DNase I hypersensitive sites (DNase-) seq (Crawford et al.,
2006) (Figures 3B and S3C–S3F). Importantly, MED1 clusters
are enriched in the vicinity of genes that are regulated in a similartemporal manner (Figure 3C), as illustrated for the acutely acti-
vated Pklr gene (Figure 3D).
ChREBP Is Acutely and Fully Activated by Glucose and
Primarily Associates with Acutely Activated Enhancers
To further investigate the mechanisms by which ChREBP medi-
ates glucose-induced enhancer and gene reprogramming in b
cells, we performed ChREBP ChIP-seq in INS-1E cells exposed
to high glucose for 0, 2, and 12 hr and identified in total 74,967
ChREBP binding sites (Figure 3E). De novo motif discovery
performed on the top 5,000 ChREBP sites identified a degen-
erate CACGTGn5CACGTG ChoRE resembling those previously
discovered by others (Figure 3F) (Jeong et al., 2011; Ma et al.,Cell Reports 16, 2359–2372, August 30, 2016 2361
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Figure 2. ChREBP Is a Central Mediator of Glucose-Induced Transcriptional Reprogramming in b Cells
(A–D) INS-1E cells were preincubated with 5 mM glucose for 24 hr and subsequently transduced with equal titers of adenovirus expressing constitutive active
ChREBP (CA-ChREBP) or GFP as control. After 2 hr, medium was replaced with fresh 5 mM medium, and INS-1E cells were harvested for total RNA-seq 12 hr
later.
(A) Density plot illustrating the correlation between expression fold-change (mRNA) induced by 25mMglucose (Figure 1) and CA-ChREBP. The red line shows the
linear regression (Pearson).
(B and C) Boxplots illustrating expression fold change (mRNA) induced by 25 mM glucose (purple) and CA-ChREBP (blue) for genes in each of the four gene
clusters defined in Figure 1C (B) and for glucose-regulated genes in the cell-cycle pathways (C, left) andMODY/insulin secretion (IS) pathways (C, right) (*p < 2.23
1016, Wilcoxon rank-sum test relative to 0).
(D) Heatmaps illustrating expression fold change (mRNA) induced by 2 hr glucose, 12 hr glucose, and CA-ChREBP for the top 20 glucose-regulated genes in the
cell-cycle pathways (D, left) and MODY/insulin secretion (IS) pathways (D, right).
(E and F) INS-1E cells were transfectedwith siRNAs targeting ChREBP (siChREBP, red) or a negative control (siControl, purple) and 2 days later preincubated with
5 mM glucose for 24 hr and subsequently treated with 5 mM or 25 mM glucose for 12 hr before harvest of RNA for mRNA-seq. The boxplots illustrate expression
fold change (mRNA) for genes induced by high glucose in siControl and siChREBP transfected cells for each of the four gene clusters defined in Figure 1C (E) and
for glucose-regulated genes in the cell cycle pathways (F, left) and MODY/insulin secretion (IS) pathways (F, right) (#p < 2.2 3 1016, Wilcoxon rank-sum test).2006; Poungvarin et al., 2015). A series of electrophoretic
mobility shift and reporter assay studies by the Towle laboratory
have indicated that whereas ChREBP is capable of binding to
perfect single E-boxes as a heterodimer with Mlx, transcriptional
activation by glucose requires binding as a heterotetramer to the
full ChoRE (Ma et al., 2005, 2007; Stoeckman et al., 2004). The2362 Cell Reports 16, 2359–2372, August 30, 2016combination of ChREBP and MED1 ChIP-seq data allowed us
to reinvestigate this in a natural chromatin context by computa-
tional mutation analysis. Specifically, we identified the best
possible match to a perfect ChoRE in each ChREBP site, divided
ChREBP sites into groups based on the number of mismatches
to each E-Box (Figure S3G), and calculated average ChREBP
binding and glucose-induced change in MED1 binding for each
of these groups. These analyses confirmed in a natural chro-
matin context and at the genome-wide level that given a perfect
CACGTG E-box, ChREBP binding is largely independent of the
number of mismatches in the second E-Box, whereas glucose-
induced enhancer activation is highly sensitive to these mis-
matches (Figures 3G and S3H). Notably, our analyses did not
support the previously reported role of ChREBP as a transcrip-
tional repressor when binding to a single E-box (Cairo et al.,
2001), since none of the groups displayed an overall loss of
MED1 following glucose exposure.
Importantly, the ChIP-seq profiles also revealed that ChREBP
binding is fully activated already following 2 hr of glucose expo-
sure (Figures 3E and 3H), indicating that ChREBP is primarily
involved in the first phase response to glucose. In line with this,
ChREBP binding is primarily enriched within early-activated en-
hancers (Figures 3I and S3I) and in the vicinity of genes acutely
induced by glucose (Figures 3J and S3J). Consistent with the re-
sults in Figure 3C, these analyses do not support a major global
role of ChREBP as a transcriptional repressor, as ChREBP bind-
ing is not enriched at any of the glucose-repressed enhancer
groups or near glucose-repressed genes (Figures 3I, 3J, S3I,
and S3J). These results place ChREBP as a master regulator
of primarily the first phase activation of genes in response to
glucose and indicate that the late induction of, e.g., cell-cycle
genes involves ChREBP-mediated induction of secondary
transcription factors.
Integrated Motif and Expression Analysis Identifies
Potential Regulators of b Cell Proliferation
To identify transcription factors involved in the second phase b
cell response to glucose, we analyzed the DNA sequences un-
derlying late regulated enhancers. General issues with such
analyses are: (1) the bias imposed by the limited number of tran-
scription factor motifs available in the database associated with
the motif tool of choice; (2) the redundancy between transcrip-
tion factors in binding motif; (3) choosing an appropriate motif
threshold; and (4) identifying the biologically relevant hits from
a rather large number of enrichedmotifs. To overcome these lim-
itations, we curated and annotated several publically available
motif databases and used a variable threshold approach to iden-
tify enriched motifs, which were subsequently systematically
filtered based on the absolute and glucose-induced change in
expression of the matching transcription factors (see Supple-
mental Information). Using this approach, we identified 234 mo-
tifs enriched within late repressed enhancers (cluster 6) and 52
motifs enriched in late activated enhancers (cluster 3) compared
with both constitutive enhancers and randomly shuffled control
regions (Figure 4A). A matching transcription factor was ex-
pressed (pr. kb R 1) at any given time point for 47 and 28 of
the motifs enriched within late repressed and activated en-
hancers, respectively. Reassuringly, the expression of transcrip-
tion factors with motifs that are enriched within late repressed
enhancers is generally repressed by glucose, whereas the
expression of transcription factors with motifs that display
enrichment in late activated enhancers is predominantly induced
by glucose (Figure 4B) (Table S3). Notably, we identified 19 po-
tential transcriptional activators of the late repressed enhancers,whose expression is also significantly downregulated by glucose
and several of these are well known regulators of b cell identity
and function (Aguayo-Mazzucato et al., 2013; Ait-Lounis et al.,
2010; Barbagallo et al., 2014; Doyle and Sussel, 2007; Harrison
et al., 1999; Heit et al., 2006; Holland et al., 2005; Jackerott
et al., 2006; Kitamura, 2013; Moore et al., 2011; Ohta et al.,
2011; Zitzer et al., 2006) (Figures 4B and 4C). In the same
manner, we identified 13 potential activators of the late-induced
enhancers, of which we chose five top candidates for further
investigation based on their fold induction by glucose and their
temporal profile of transcriptional activation (cluster 1) (Fig-
ure 4B). Interestingly, knock down of four out of five of these fac-
tors significantly reduced the induction of cell-cycle genes by
glucose as determined by mRNA-seq (Figure 4D). This further
supports a role of these glucose-induced transcription factors
in mediating ChREBP-induced b cell proliferation. Notably,
knock down of one of the four factors had limited if any effect
on expression of the other factors (Figures S4A–S4D), indicating
that these factors play relatively independent roles in the cell-
cycle gene program. The fact that siBHLHE40 does not affect
cell-cycle gene expression may be due to the poor knockdown
efficiency of this siRNA pool (Figure S4E).
RORg Is a Direct ChREBP Target Involved in
Glucose-Induced b Cell Proliferation
Besides MYCN, which is a well-known regulator of cell prolifera-
tion (Bell et al., 2010), depletion of the nuclear receptor RORg
displayed the largest impact on glucose induction of cell-cycle
genes. RORg is a diurnal regulator with well-defined functions
in liver and adipose tissues that appear to promote insulin resis-
tance in mice fed an obesogenic diet (Meissburger et al., 2011;
Takeda et al., 2014); however, little is known about the function
of RORg in b cells. Interestingly, we observed a prominent
glucose-activated, ChREBP-bound enhancer 1 kb upstream of
the promoter of the Rorc gene (Figure 5A) and this enhancer is
also conserved in human pancreatic islets (Encode, 2012) and
in isolated human primary b cells (Ackermann et al., 2016) (Fig-
ure 5B). The Rorc 1 kb enhancer contains several putative
ChoREs that are highly conserved in the mouse and human ge-
nomes (Figures 5C, 5D, S5A, and S5B), suggesting that activa-
tion ofRorc expression by ChREBP involves cooperative binding
to multiple ChoREs within this enhancer. Consistent with Rorc
being a direct target gene of ChREBP, ChREBP depletion signif-
icantly blunts glucose induction of nascent Rorc transcript after
both 2 hr and 12 hr (Figure 5E). The acute induction of nascent
Rorc transcript levels by glucose is followed by accumulation
of the mature mRNA of Rorc and in a further delayed manner
of RORg protein levels (Figures 5F and S5C), consistent with a
role of RORg in late gene regulation by glucose. The induction
of Rorc expression by glucose is also observed in human
pancreatic islets cultured ex vivo (Figures 5G and S5D).
Interestingly, further analyses of the mRNA-seq data obtained
from siRORg- and siControl-transfected INS-1E cells suggests a
selective role of RORg in activation of the late glucose-induced
gene program including cell-cycle genes (Figures 6A and 6B).
Transfection with siRORg reduced RORg protein levels by
80% (Figure S5C) and did not affect mRNA levels of Rora or
Rorb (Figure S6). Importantly, the glucose-induced proliferationCell Reports 16, 2359–2372, August 30, 2016 2363
(legend on next page)
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rate of INS-1E b cells, assessed by bromodeoxyuridine (BrdU)
incorporation, is significantly decreased in siRORg-transfected
cells (Figure 6C), and to test the relevance of this finding in pri-
mary b cells, we cultured isolated rat pancreatic islets for 48 hr
in the presence of 5 or 20 mM glucose in combination with the
RORg antagonist SR2211 or DMSO. Indeed, SR2211 treatment
significantly reduced glucose-induced b cell proliferation in rat
islets as assessed by 5-ethynyl-20-deoxyuridine (EdU) incorpo-
ration (Figures 6D and 6E). Taken together, these data support
an important role for ChREBP-mediated induction of RORg
expression in the induction of b cell proliferation by glucose.
DISCUSSION
Glucose has profound long-term effects on b cell function that
can lead to both increased proliferative potential and compro-
mised b cell function. These adaptive changes have been re-
ported to involve several different transcription factors including
ChREBP; however, the molecular mechanisms underlying the
pleiotropic effects of glucose and ChREBP are not well under-
stood. Here, we profile changes in enhancer and transcriptional
activity in response to glucose in pancreatic b cells, and we use
these data to define a central role for ChREBP as initiator of
the response and to identify transcription factors (TFs) acting
downstream of ChRBEP. In particular, we identify RORg as a
ChREBP-induced regulator of b cell proliferation.
Similar to previous studies on the role of ChREBP in regulation
of b cell proliferation and function (Metukuri et al., 2012; Poung-
varin et al., 2012), we treated INS-1E cells with 25 mM glucose
for up to 12 hr following preincubation at 5 mM glucose. This
setup allows for detailed temporal analyses to dissect the tran-
scriptional networks involved in establishing and/or acting in a
situation of chronically elevated glucose levels. While the setup
is not directly comparable to the more modest increase in blood
glucose levels observed in diabetics that occurs progressively
over much longer periods, the genes regulated by glucose inFigure 3. MED1 and ChREBP ChIP-Seq in Glucose Stimulated INS-1E
Following 24 hr preincubation in 5 mM glucose medium, INS-1E cells were switch
reverse time course before harvest of all samples for ChIP-seq or DNase-seq at
(A) Fuzzy cluster analysis of the temporal changes in enhancer activity, as ass
difference [FDR% 0.05] between 5 mM glucose and 2 or 12 hr of stimulation wit
(B) Heatmaps illustrating average MED1 signal, DNase I accessibility, and eRNA
treated with high glucose for 0, 2, or 12 hr.
(C) Heatmap illustrating location of enhancer clusters defined in (A) relative to the g
clusters within 50 kb of the transcription start site (TSS) of genes in the four gene
genes.
(D) UCSC Genome Browser screenshots of MED1- and DNase I signal at the ge
(E) Heatmap showing ChREBP binding intensity in a 4 kb window around the c
(25 mM) for 0, 2, and 12 hr.
(F) Motif identified by de novomotif analysis of the top 5,000 identified ChREBP bin
Ma et al. (2006), Jeong et al. (2011), and Poungvarin et al. (2015) (below) are sho
(G) Heatmaps representing motif dependency for ChREBP binding and enhancer
on the number of mismatches of the best possible ChoRE half site in each site
binding intensity (G, top) and log2 fold change in MED1 occupancy in response to
group of binding sites.
(H) Violin plot representing fold change in ChREBP binding in response to 25 mM
(I) Boxplots illustrating ChREBP occupancy (2 hr) at glucose-regulated enhancer
(J) Boxplots representing summarized ChREBP occupancies (2 hr) at all ChREBP
in Figure 1C. The indicated p values were calculated using the Wilcoxon rank-suINS-1E cells tend to be also differentially expressed in a similar
manner in islets from type 2 diabetic subjects relative to islets
from healthy control subjects. This indicates that the glucose-
treated INS-1E cells recapitulate at least some features of dia-
betic islets.
Our time-resolved profiles of changes in transcription and
enhancer activity show that the response to glucose is biphasic.
Genes involved in glucose and lipid metabolism are acutely acti-
vated in a first wave, which is followed by a second wave during
which cell-cycle genes are activated and b cell identity genes are
repressed.We demonstrate by gain- and loss-of-function exper-
iments that ChREBP is involved in both gene activation and
repression of genes in both waves, which is in line with recent
studies that have implicated ChREBP in both the proliferative
(Metukuri et al., 2012) and toxic (Poungvarin et al., 2012) effects
of glucose on pancreatic b cells. However, our genome-wide an-
alyses show that ChREBP binding is primarily associated with
enhancers that are activated in the first wave, indicating that acti-
vation of the second wave enhancers as well as repression by
ChREBP is mostly indirect. ChREBP has previously been re-
ported to have repressor function (Boergesen et al., 2011; Cairo
et al., 2001); however, the fact that ChREBP is not enriched at
repressed enhancers in glucose-stimulated INS-1E cells does
not support a major global role of ChREBP as a transcriptional
repressor in the classical sense in this system. We consider it
likely that acute repression occurs by cofactor redistribution as
demonstrated for nuclear receptors and NFkB (Schmidt et al.,
2016), but further experiments are needed to rule out contribu-
tions from alternative mechanisms such as deactivation of other
TFs by high glucose.
Given the biphasic repression of gene expression, it is likely
that decreased expression/activity of transcriptional activators
acutely repressed by glucose over time leads to second wave
repression. The strength in profiling enhancer activity is that we
can predict TFs involved in the various phases of the response
by bioinformatic analysis of motif enrichment within specificb Cells
ed to fresh 5 mMmedium and 25mM glucose was added for 0, 2, and 12 hr in a
the same time.
essed by MED1 read counts, of all dynamic enhancers (i.e., enhancers with
h 25 mM glucose).
levels for the six different MED1 clusters of regulated enhancer in INS-1E cells
ene clusters defined in Figure 1C. The enrichment of the six different enhancer
clusters is plotted relative to the number of enhancers found near constitutive
ne locus of a typical cluster 1 gene Pklr.
enter of all identified ChREBP sites in INS-1E cells treated with high glucose
ding sites (top). The ChREBP bindingmotifs identified in three different studies:
wn.
activation by glucose. All identified ChREBP binding sites were grouped based
compared with a perfect ChoRE. See also Figure S3G. The average ChREBP
2 hr exposure to high (25 mM) glucose (G, bottom) were determined for each
glucose exposure for 2 versus 0 hr (H, left) and 12 versus 2 hr (H, right) of.
clusters defined in (A).
binding sites within 50 kb of the TSS of glucose-regulated gene clusters defined
m test.
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Figure 4. Identification of Potential Second Wave Regulators by Integrated Motif and Expression Analysis
(A) Heatmap representing motifs enriched within late repressed (cluster 6, red) or activated (cluster 3, green) enhancers as defined in Figure 3A.
(B) Heatmap illustrating fold change in expression (mRNA, 12 versus 0 hr) for TFs with enriched motifs in late repressed (B, top) or late activated (B, bottom)
enhancers. TFs whose expression is significantly regulated by glucose in the same direction as the activity of the enhancer cluster in which their motif is enriched
are listed. The listed TFs are color coded according to the temporal profile of their primary transcript levels as defined in Figure 1C.
(C) Table listing potential activators of late repressed enhancers with known regulatory roles of b cell gene expression, identity, and function.
(D) INS-1E cells were transfected with a negative control siRNA (siControl, dark purple) and siRNAs targeting five potential activators of the second wave en-
hancers activated by glucose identified in (A) and (B) (light purple). 2 days later, cells were preincubatedwith 5mMglucose for 24 hr and subsequently treatedwith
5 mM or 25mM glucose for 12 hr before harvest of RNA for mRNA-seq. The boxplot illustrates expression fold change (mRNA) induced by glucose in control and
knockdown cells for glucose-activated genes in the cell-cycle pathway (*p < 2.2 3 1016, Wilcoxon rank-sum test relative to siControl).enhancer clusters. In this work, we have used an approach that
integrates motif enrichment with expression profiles of the corre-
sponding TFs, thereby improving the prediction of TFs involved
in changing enhancer activity. The approach relies on the fact
that most mammalian TFs act to promote transcription at their
binding sites (Hurst et al., 2014) and identifies factors whose
mRNA expression is regulated congruently with the activity of
the temporal cluster of enhancers in which the corresponding
motif is enriched. The approach does not take changes in TF ac-
tivity by posttranslational modifications into consideration, but
focuses onmRNA expression of the TF as an estimate of activity.2366 Cell Reports 16, 2359–2372, August 30, 2016Thus, the approach is particularly useful for identifying regulators
of the second wave transcriptional response, because these are
likely to be transcriptionally modulated by the first wave TFs. By
this approach, we could reduce a list of 234 TF with motifs en-
riched within late repressed enhancers to a set of 18 potential
transcriptional regulators of the late repressed enhancers whose
expression is also significantly downregulated by glucose.
Interestingly, and as a validation of our approach, the potential
regulators of late repressed enhancers include well-known reg-
ulators of b cell identity like PDX1 (Holland et al., 2005) and
NKX2-2 (Doyle and Sussel, 2007). Among the acutely repressed
Figure 5. RORg Is a ChREBPTarget inbCells
(A) UCSC Genome Browser screenshots of MED1-
and ChREBP-occupancy at the Rorc locus in INS-
1E cells treated with 25 mM glucose for 0 hr, 2 hr,
and 12 hr. The gray bar marks the identified
ChREBP-bound Rorc 1 kb enhancer.
(B) UCSC Genome Browser screenshots displaying
DNase-seq signal at the RORC locus in human
pancreatic islets (Encode, 2012) (B, top) and ATAC-
seq signal in isolated primary human b cells (Ac-
kermann et al., 2016) (B, bottom). The gray bars
mark the orthologous region corresponding to the
rat Rorc 1 kb enhancer.
(C) Sequence of the central rat Rorc 1 kb
enhancer. The three non-overlapping putative
ChoREs (2, 5, and 7) with the highest predicted
combined activity are depicted. See also Figures
S5A and S5B.
(D) Conservation and predicted activities of
ChoRE2, ChoRE5, and ChoRE7 in the mouse and
human genomes. The activities were predicted
based on the number of mismatches to the primary
and secondary E-box as described in Figures 3G,
S3G, and S3H. See also Figure S5B. The bars
indicate mean and 95% confidence intervals of
glucose activation (log2 fold change [MED1 2 hr /
MED1 0 hr]).
(E) Bar diagram showing nascent Rorc transcript
levels in siChREBP or siControl transfected cells
treated with high glucose for 0, 2, or 12 hr.
(F) Nascent (light gray) and mature (dark gray)
transcript levels of Rorc and protein levels of RORg
(black) in INS-1E cells treated with 25 mM glucose
for 0, 1, 2, 4, and 12 hr. The percentages relative to
the level at 12 hr are plotted.
(G) Dot blots representing glucose-induced log2
fold changes from all six individual donors in the
three studies analyzed in Figure S5D. The squares
represent (Brun et al., 2015) (Figure S5D, left), the
circles represent (Bagge et al., 2012) (Figure S5D,
center), the triangle represents (Boergesen et al.,
2011) (Figure S5D, right), and the black bar repre-
sents the average of all samples. The indicated
p value was calculated using a one-tailed Student’s
t test.factors, RFX3 and FOXO1 are particularly interesting, as RFX3 is
required for proper b cell differentiation and function (Ait-Lounis
et al., 2010), and b cell specific FOXO1 ablation in mice leads to
increased susceptibility to b cell dedifferentiation by metabolic
stress (Talchai et al., 2012). As several of the identified TFs are
known to regulate the expression of each other, we furtherCell Rehypothesize that the acute repression of
TFs like RFX3 and FOXO1 initiates an
amplifying feedforward mechanism even-
tually leading to the delayed full repression
of b cell identity genes including genes
in the MODY and insulin secretion path-
ways. Importantly, from these analyses,
several potential regulators of b cell iden-
tity emerge, including HMX1, HOXC13,
and BARHL1. The role of these in b celldevelopment, function, and dedifferentiation should be further
investigated.
Similarly, the rapid induction of ChREBP binding and the
limited enrichment hereof at late-activated enhancers, indicate
that ChREBP mediate the late effects of glucose through induc-
tion of secondary transcriptional regulators, the accumulation ofports 16, 2359–2372, August 30, 2016 2367
Figure 6. RORg Is Required for Glucose-
Induced b Cell Proliferation
(A) Bar diagram illustrating the overlap between
RORg-dependent genes and the four gene clus-
ters defined in Figure 1C. RORg dependent genes
were defined by a one-sided Student’s t test be-
tween log2 fold changes in siControl and siRORg
and the significance in a one-sided chi-square
test of the overlap between the list of RORg-
dependent genes and the four gene clusters
defined in Figure 1C compared with constitutive
genes was calculated.
(B) Heatmap illustrating pathway enrichment of
genes differentially regulated in siRORg- versus
siControl-transfected cells.
(C) Bar diagram representing proliferation of INS-
1E cells in siControl- and siRORg-transfected
cells. The cells were transfected with siRNA and
48 hr later preincubated in 5 mM glucose for 24 hr
followed by 24 hr exposure to 5 or 25mMglucose.
BrdU was added 6 hr prior to harvest and subse-
quently quantified by ELISA. The bars represent
mean and SEM of three independent experiments.
(D and E) Pancreatic islets isolated from adult rats
were seeded onto coverslips and cultured for
48 hr in 5 or 20 mM glucose medium supple-
mented with RORg antagonist SR2211 (20 mM) or
DMSO, and b cell proliferation was assessed by
EdU incorporation.
(D) Representative immunocytochemical staining
of rat pancreatic islets cultured with glucose and
SR2211 as indicated and stained for EdU (red),
insulin (green), and DNA/Hoechst (blue).
(E) Bar diagrams representing the fractions of
EdU+/Ins+ positive cells in pancreatic islets
cultured with glucose and SR2211 as indicated.
The bars represent mean and SEM of 3–4 inde-
pendent biological experiments. The indicated
p values were calculated using a one-tailed Stu-
dent’s t test (C and E).which results in activation of the second wave gene program.
Interestingly, the Scott laboratory recently showed that induction
of ChREBPb, a truncated constitutive active isoform of ChREBP
which is induced by ChREBP itself (Herman et al., 2012), is
required for glucose-induced b cell proliferation (Zhang et al.,
2015). The finding that ChREBPb is a ChREBPa target gene sug-
gests that it could activate second wave enhancers; however,
since ChREBP binding sites are not enriched in these enhancers,
we consider it more likely that ChREBPb amplifies the ChREBPa
activity in the first wave enhancers. By applying our integrative
approach to late activated enhancers, we identified 53 enriched
motifs for which 13 of the corresponding TFs are transcriptionally
activated by glucose. Whereas the function and role of multiple
of the potential regulators of late repressed enhancers and b
cell identity genes are well characterized, the potential of the
identified late activators have not been described in the context
of b cell proliferation. Furthermore, with MYCN as the exception,
little is known about the role of these factors in cell proliferation in
general. We therefore investigated these factors by siRNA-medi-
ated knockdown and confirmed a role for MYCN, ATF4, GATA4,
and RORg in the induction of cell-cycle genes by glucose in
INS-1E b cells. We propose that these ChREBP-induced factors2368 Cell Reports 16, 2359–2372, August 30, 2016cooperate to mediate the full induction of cell-cycle genes and b
cell proliferation by glucose. Further investigations of these
ChREBP-induced secondary regulators of b cell proliferation
may outline opportunities for specific modulation of b cell prolif-
eration in T2D therapy.
We chose to focus on the nuclear receptor RORg for further
investigations, and we demonstrated that the Rorc gene
encoding RORg is a direct target of ChREBP and acutely
activated by glucose. Further analyses of RNA-seq data
from RORg-depleted cells indicated that RORg is selectively
involved in regulation of the late induced gene program,
including cell-cycle genes, by glucose. Importantly, RORg ac-
tivity is required for full glucose-induced proliferation of both
INS-1E cells and b cells within primary rat islets cultured
ex vivo, further indicating a positive role of RORg in b cell adap-
tation in response to metabolic stress. Such a role may seem
contradictory to the phenotype of RORg/ mice, which
exhibit improved insulin sensitivity and glucose tolerance on a
high fat diet (Meissburger et al., 2011; Takeda et al., 2014);
however, these effects appear to be due to RORg action in ad-
ipose tissue (Meissburger et al., 2011) and liver (Takeda et al.,
2014). Future studies should investigate the b cell-specific role
Figure 7. Model of Glucose-Induced, ChREBP-Mediated Reprogramming of the b Cell Enhancer and Gene Landscape
Following glucose treatment, ChREBP activates genes encoding metabolic enzymes and induces the expression of a set of transcriptional regulators including
RORg, the accumulation of which results in induction of the cell-cycle gene program. Additionally, and possibly by ChREBP-mediated cofactor redistribution,
glucose treatment acutely leads to repression of genes encoding transcriptional regulators like RFX3 and FOXO1, the downregulation of which may facilitate the
delayed repression of b cell identity genes.of RORg in response to metabolic stress and explore the ability
of RORg agonists to promote b cell proliferation in vivo. From
a therapeutic perspective, it is promising that short term admin-
istration of a dual RORa/g agonist was recently shown to
improve glucose tolerance in mice, although this was sug-
gested to be facilitated by a RORa-mediated increase in insulin
expression (Kuang et al., 2014). Conversely, potential unde-
sired effects of RORg antagonists on b cell proliferation should
be considered when exploring the use of these antagonists as
potential insulin-sensitizing drugs due to their inhibition of
RORg in liver and adipose tissue. It will also be important to
define the mechanism of RORg action including the identifica-
tion of the direct target genes of RORg and to determine the
importance of crosstalk with the other cell-cycle regulators
induced by glucose.
In conclusion, our work shows that high glucose leads to a
biphasic change in gene expression in INS-1E cells, where
cell-cycle genes are activated, and b cell genes are repressed
in the second wave (Figure 7). ChREBP acts as a master regu-
lator of the transcriptional response to glucose, but is primarily
directly associated with enhancers activated in the first wave,
whereas enhancers activated in the second wave appear to
be activated by ChREBP-induced TFs. These include RORg,




The INS-1E cell line (Merglen et al., 2004) was cultured as previously described
(Boergesen et al., 2011) and used between passage numbers 60 and 90. Prior
to exposure to high (25 mM) glucose, cells were preincubated with 5 mM
glucose medium for 24 hr. Time course experiments were performed in areverse manner, i.e., medium was changed on all cells at time point 0 hr,
whereafter 25 mM glucose was added to the medium at consecutive time
points and all cells were harvested at the 12 hr time point.
Pancreatic islets were isolated from adult rats (8- to 10-week-old
Sprague-Dawley) by collagenase infusion via the common bile duct as pre-
viously described (Roeske-Nielsen et al., 2010). For proliferation experi-
ments, islets were cultured for 72 hr in RPMI 1640 supplemented with
10% FCS and 1% penicillin-streptomycin with media change daily, before
seeding overnight onto Matrigel-coated (Corning) coverslips (10–30 islets
per coverslip) in RPMI 1640 supplemented with 2% pooled human serum
(MP Cellect) and 1% penicillin-streptomycin. The care of rats was within
Institutional Animal Care and Use Committee (IACUC) guidelines. Analysis
of RORC expression in human islets in Figures 5G and S5D was performed
on material previously collected, and detailed information on isolation,
culture, and treatment of human islets for the experiments can be found
in (Bagge et al., 2012; Boergesen et al., 2011; Brun et al., 2015). The
use of human tissue for research was approved by the local ethical
committees.
RNA Extraction, cDNA Synthesis, and Quantitative Real-Time PCR
Following Isol-RNA lysis Reagent (5-Prime) extraction and EconoSpin (Epoc
Life) column purification of total RNA, cDNA synthesis, and quantitative real-
time PCR (qPCR) were performed as previously described (Boergesen et al.,
2011). Sequences of primers used for qPCR are available in Table S4.
RNA-Seq
For total RNA-seq, contaminant genomic DNAwas removed from purified total
RNA by TURBO DNase digestion (Life Technologies), and rRNAs were
removed using the Ribo-Zero Human/Mouse/Rat kit (Epicenter). For mRNA-
seq, 1 mg total RNA was incubated with poly-dT beads to isolate polyadeny-
lated RNA. RNA fragmentation and cDNA synthesis was performed according
to the manufacturer’s instructions (TruSeq 2, Illumina).
ChIP-Seq
ChIP experiments were performed according to standard protocol as
described (Siersbæk et al., 2012). Antibodies used were ChREBP (NB400-
135, Novus Biologicals) and MED1 (M-255, sc-8998, Santa Cruz).Cell Reports 16, 2359–2372, August 30, 2016 2369
DNase-Seq
DNase-seq was performed on 10 million nuclei essentially as previously
described (Siersbæk et al., 2011).
Library Construction and Sequencing
RNA-, DNase-, and ChIP-seq libraries were constructed using PentAdapters
(Pentabase) essentially as described in Nielsen and Mandrup (2014).
Sequencing was performed on the Illumina HiSeq 1500 platform.
Adenoviral Transduction
The CA-ChREBP adenovirus used was generated and produced as previ-
ously described (Boergesen et al., 2011). INS-1E cells were preincubated
for 24 hr, incubated with equal titers of CA-ChREBP or GFP control adeno-
virus for 2 hr, and incubated with 5 mM glucose for 12 hr before harvest
of RNA.
siRNA-Mediated Knockdown
At 1 day prior to transfection, INS-1E cells were seeded in antibiotic-free cul-
ture medium at a density of 800,000 cells/cm2. A transfection mix (750 nM
siRNA [Sigma-Aldrich] and 5% v/v DharmaFECT [Thermo]) prepared in serum-
and antibiotic-free OptiMEM media (Gibco) was added to the cells in a 1:5 ra-
tio. The following day, the media was changed to standard RPMI, and the cells
were incubated for 2 days prior to any experiment. Oligo sequences are avail-
able in Table S4.
Western Blotting and ECL Detection
Whole cell extracts were prepared in SDS-containing buffer and subjected
to western blotting as previously described (Nielsen et al., 2006). The
following primary antibodies were used: anti-ChREBP (sc-21189, Santa
Cruz Biotechnology) and anti-RORg (MAB6109; R&D systems). Anti-
HSP90 (sc-7947, Santa-Cruz Biotechnology) or anti-TFIIB (sc-225, Santa
Cruz Biotechnology) was included as loading controls. The following sec-
ondary antibodies were used: anti-rabbit IgG (P0399, Dako) and anti-
mouse IgG (P0447, DAKO). Densitometry was used to quantify protein
expression.
Cell Proliferation Assays
Proliferation of INS-1E cells was determined by BrdU incorporation. Briefly,
cells were preincubated for 24 hr in 5mMglucosemedium and then stimulated
with either 5 mM glucose or 25 mM glucose for 24 hr. BrdU was added to the
medium for the last 6 hr before the cells were fixed. Following DNA denatur-
ation, the amount of BrdU incorporation was assessed immunochemically
as described in the manufacturer’s (Millipore) protocol.
Proliferation of primary rat b cells was assessed by EdU-incorporation in
intact rat pancreatic cultured ex vivo essentially as described in Bruun et al.
(2014). For investigation of glucose-stimulated b cell proliferation, medium
was changed to either 5 mM or 20 mM glucose medium supplemented with
20 mM SR2211 (Millipore) or DMSO for 48 hr. EdU was supplemented to all
conditions for the full 48 hr at a concentration of 10 mM (Click-IT EdU, Invitro-
gen). Following stimulation, islets were fixed in 4%paraformaldehyde, washed
in PBS, and permeabilized in 17%DMSObefore EdU detection and stained for
insulin using guinea pig anti-insulin (Ab7842, Abcam) followed by visualization
using Dylight488 conjugated goat-anti-guinea pig (Ab102374, Abcam).
Hoechst 33342 was used for nuclear counterstaining. z stack images were
captured by confocal microscopy (Zeiss LSM 510) and counted using Fiji
(http://www.fiji.sc/). A minimum of 3,500 Ins+ cells were counted in total per
condition.
Additional Data Sets
The following publically available data sets were used in this work: RNA-seq
data from the rat body map (Yu et al., 2014) (GEO: GSE53960), microarray
data from glucose treatment of rat pancreatic islets (Bensellam et al., 2009)
(GEO: GSE12817), microarray data from pancreatic islets of human type 2 dia-
betic and control subjects (Taneera et al., 2012) (GEO: GSE38642), DNase-seq
data from human pancreatic islets (Encode, 2012) (GEO: GSM816660), and
ATAC-seq data from isolated human primary b cells (Ackermann et al., 2016)
(GEO: GSE76268).2370 Cell Reports 16, 2359–2372, August 30, 2016Statistical Analysis
Bar diagrams illustrating qPCR or proliferation analyses are represented as
mean + SE. The indicated p values were calculated using a one-tailed
Student’s t test. RNA- and ChIP-seq data were analyzed for differential
expression or occupancy using iRNA-seq (Madsen et al., 2015) and edgeR
(Robinson et al., 2010), respectively. Cluster analyses were performed using
fuzzy c-means clustering (Maechler et al., 2016). Differences in expression
strength or occupancy between gene and enhancer groups were tested using
non-parametric Wilcoxon ranked-sum tests. The significance of any enrich-
ments or overlaps was determined by random permutation, chi-square tests,
or linear regression as indicated in the figures.
Detailed descriptions of the computational analyses used in this study are
available in the Supplemental Information.
ACCESSION NUMBERS
The accession number for the sequencing data sets reported in this paper is
GEO: GSE81628.
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